Strengthening Neuroscience Clinical Research Through Innovation

There’s a lot of discussions these days about innovative ideas to make clinical research more patient-focused. The concept goes hand-in-hand with the development of technology that permits researchers to design and execute trials that can significantly reduce the burden of participation.

Development of neuroscience drugs is benefiting from these advances in patient-focused research, as new technologies and approaches are challenging traditional research models. This webinar will explore innovative technology being used to collect data in neuroscience trials, including wearables, remote medication compliance monitoring, data analytics and even virtual study visits to enhance compliance, data quality and patient-centricity.

 In this free webinar, the featured speakers will discuss: 

• How new technologies can make neuroscience trials more productive, efficient and the endpoints more objective
• How these technologies can improve patient engagement and reduce patient burden, while raising new regulatory/operational concerns
• How new technologies such as wearable devices, remote monitoring, and virtual patient visits have the potential to make trials more patient-friendly, whilst improving the speed and reliability of the studies
• How social media provides many opportunities to increase patient engagement

Speakers

Juliet M. Moritz, Vice President, Patient & Stakeholder Engagement, Premier Research

Juliet Moritz is a highly experienced pharmaceutical professional with over 30 years of clinical research experience. She joined Premier Research in 2016, assisting customers with the strategic development of products to address unmet medical needs associated with rare and orphan diseases. Prior to joining Premier Research, Juliet held positions of increasing responsibility in small to large pharmaceutical companies and CROs, including but not limited to, Associate Director, Clinical Research and Development (Knopp Biosciences), Associate Director, Global Project Management and Strategic Alliance Lead (large CRO), and Director of Global Compliance Auditing – Safety Surveillance and Education (Wyeth), among others.

Juliet has been involved in the development and implementation of clinical plans for more than 20 years and brings this experience with her to Premier Research and their customers. She has spent years working on programs for the identification and treatment of rare diseases. She has extensive experience supporting research that spans the range from single-site studies to large, multinational trials. In addition to supporting overall rare disease and pediatric research strategy, Juliet brings her passion for patient centricity to every program she works on, partnering with clients to maximize relationships with patients, their caregivers and their advocates.

Juliet completed her undergraduate work in biology and nursing at the University of Pennsylvania. She earned her Master of Public Health degree with honors at the School of Public Health at Drexel University and is currently pursuing her doctorate in bioethics through the Alden March Bioethics Institute of Albany Medical College. She is also in the process of completing a professional development certificate in Genetics and Genomics offered by Stanford University.

 

Message Presenter

Barry Dussault, Executive Director, Program Delivery, Neuroscience, Premier Research

In his role at Premier Research, Barry Dussault has taken the lead in Parkinson’s and other movement disorders from the operations side. Prior to joining Premier, Mr. Dussault, was Senior Director of Therapeutic Strategy Lead (Neuroscience) at a large CRO and led clinical operations at two venture-stage biotechnology companies, CoLucid Pharmaceuticals and Hypnion, in the migraine and insomnia therapeutic areas, respectively. 

Mr. Dussault has worked in all aspects of drug development during his 20+ year career, from target discovery at the bench, to managing preclinical toxicology studies and formulation development, to Phase I pharmacokinetics and Phase II proof-of-concept studies for biotechnology companies. While working at CROs, he led study teams in opioid addiction, smoking cessation, pain and CNS rare diseases, in both the US and in Europe.

Mr. Dussault holds an MBA (with highest distinction) from Bentley University in Waltham, MA and a Bachelor of Science in Biological Sciences from the University of Massachusetts-Lowell. 

Message Presenter